NDC 0173-0896
Blenrep
Belantamab
Blenrep is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Glaxosmithkline Llc. The primary component is Belantamab Mafodotin.
| Product ID | 0173-0896_0952ef08-388d-45c1-aa91-3e5a47bc9acd |
| NDC | 0173-0896 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Blenrep |
| Generic Name | Belantamab |
| Dosage Form | Injection, Powder, Lyophilized, For Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2020-08-05 |
| Marketing Category | BLA / BLA |
| Application Number | BLA761158 |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | BELANTAMAB MAFODOTIN |
| Active Ingredient Strength | 50 mg/mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 0173-0896-01
1 VIAL in 1 CARTON (0173-0896-01) > 2 mL in 1 VIAL
| Marketing Start Date | 2020-08-05 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Drug Details
Trademark Results [Blenrep]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 BLENREP 98155191 not registered Live/Pending |
Glaxo Group Limited 2023-08-29 |
 BLENREP 86451001 5258533 Live/Registered |
Glaxo Group Limited 2014-11-11 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.